PMID- 12759442
OWN - NLM
STAT- MEDLINE
DCOM- 20030902
LR  - 20190516
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 170
IP  - 11
DP  - 2003 Jun 1
TI  - Dendritic cell-based immunotherapy combined with antimony-based chemotherapy 
      cures established murine visceral leishmaniasis.
PG  - 5625-9
AB  - Dendritic cells (DCs) have been proposed to play a critical role as adjuvants in 
      vaccination and immunotherapy. In this study we evaluated the combined effect of 
      soluble Leishmania donovani Ag (SLDA)-pulsed syngeneic bone marrow-derived 
      DC-based immunotherapy and antimony-based chemotherapy for the treatment of 
      established murine visceral leishmaniasis. Three weekly injections of SLDA-pulsed 
      DCs into L. donovani-infected mice reduced liver and splenic parasite burden 
      significantly, but could not clear parasite load from these organs completely. 
      Strikingly, the conventional antileishmanial chemotherapy (sodium antimony 
      gluconate) along with injections of SLDA-pulsed DCs resulted in complete 
      clearance of parasites from both these organs. Repetitive in vitro stimulation of 
      splenocytes from uninfected or L. donovani-infected mice with SLDA-pulsed DCs led 
      to the emergence of CD4(+) T cells with characteristics of Th1 cells. Our data 
      indicate that DC-based immunotherapy enhances the in vivo antileishmanial 
      potential of antimony or vice versa.
FAU - Ghosh, Monidipa
AU  - Ghosh M
AD  - Division of Immunology, Indian Institute of Chemical Biology, Jadavpur, Kolkata, 
      India.
FAU - Pal, Chiranjib
AU  - Pal C
FAU - Ray, Mitali
AU  - Ray M
FAU - Maitra, Sudipta
AU  - Maitra S
FAU - Mandal, Labanya
AU  - Mandal L
FAU - Bandyopadhyay, Santu
AU  - Bandyopadhyay S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigens, Protozoan)
RN  - 0 (Antiprotozoal Agents)
RN  - 0 (Protozoan Vaccines)
RN  - 9IT35J3UV3 (Antimony)
SB  - IM
MH  - Adoptive Transfer/*methods
MH  - Animals
MH  - Antigen-Presenting Cells/immunology/parasitology/transplantation
MH  - Antigens, Protozoan/therapeutic use
MH  - Antimony/*therapeutic use
MH  - Antiprotozoal Agents/*therapeutic use
MH  - Combined Modality Therapy
MH  - Dendritic Cells/immunology/parasitology/*transplantation
MH  - Injections, Intramuscular
MH  - Injections, Intravenous
MH  - Leishmania donovani/drug effects/growth & development/immunology
MH  - Leishmaniasis, Visceral/*drug therapy/*immunology/parasitology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Protozoan Vaccines/immunology/*therapeutic use
MH  - Solubility
MH  - Th1 Cells/immunology/metabolism/parasitology
EDAT- 2003/05/22 05:00
MHDA- 2003/09/03 05:00
CRDT- 2003/05/22 05:00
PHST- 2003/05/22 05:00 [pubmed]
PHST- 2003/09/03 05:00 [medline]
PHST- 2003/05/22 05:00 [entrez]
AID - 10.4049/jimmunol.170.11.5625 [doi]
PST - ppublish
SO  - J Immunol. 2003 Jun 1;170(11):5625-9. doi: 10.4049/jimmunol.170.11.5625.